Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.

Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.